Life Science Leader Magazine

NOV 2014

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link: https://lifescienceleadermag.epubxp.com/i/406276

Contents of this Issue

Navigation

Page 44 of 53

43 LIFESCIENCELEADER.COM NOVEMBER 2014 the adaptive immune system but also the innate system. E s s e n t i a l c o m p o n e n t s ? [SEETO] Everything is driven by the science, and we need to conduct more for us is not just immunostimulators and checkpoint inhibitors, not just the gas on and brakes off. We are looking at the tumor microenvironment and promoting the enhancement of tumor antigen pre- sentation, so we are focused not only on data has also indicated that biomarkers and genetic signatures may be used to identify the patient population that will best respond to treatment, but validation of the biomarkers for selection has yet to be confirmed in the clinic. G e n e ra l c o m m e n t ? We highly value our preclinical data as a driver for clinical programs. We believe that well-conducted studies may help with the rational design of combination therapies and can assist in the appropriate design of clinical trials. Having said that, demonstrating a mechanism of action for the therapy in patients early on is criti- cal to justify further development. This will allow for more efficient, effective, and innovative clinical trial designs that will translate into effective cancer therapies. M E D I M M U N E /A S T R A Z E N E C A Numerous immunotherapies in development, including MEDI4736 (PD-L1) now in Phase 3, tremelim- umab (CTLA-4, licensed from Pfizer), MEDI6469 (OX40, from AgonOx), and MEDI0680 (PD-1, acquired through Amplimmune). BAHIJA JALLAL, PH.D. Executive Vice President, AstraZeneca, Head of MedImmune EDWARD BRADLEY, M.D. Senior Vice President, R&D; Oncology, iMED Head REG SEETO, M.D. Vice President, Head of Partnering and Strategy W h y c o m b i n a t i o n s ? [BRADLEY] We believe in combinations and have a robust clinical portfolio with CTLA-4, PD-1, PD-L1, and OX40 in devel- opment both as monotherapy and in com- binations. The next wave of combinations

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine - NOV 2014